There’s a strange stillness that follows chaos. Maybe it’s exhaustion. Maybe it’s clarity. Or maybe it’s just the sound of truth finally pushing through the noise. I’ve spent my life being forthright ...

Purpose-Built AI Agents Eliminate Hours of Manual Test Analysis, Accelerating Release Cycles and Empowering Engineering Teams to Ship High-Quality Applications with Unprecedented Speed and Confidence ...

Euro System is not just another trading interface. It represents a new era of intelligent investment empowerment, where ...

Indiana boasts a high-powered offense led by Heisman-hopeful Fernando Mendoza and an elite defense that ranks Top 5 ...

The Age of AI will rely on massive volumes of data that can be easily stored and retrieved—and bioscience may have an ingenious solution. A scientist examines a DNA (deoxyribonucleic acid) profile on ...

Q3 2025 Earnings Call Transcript November 6, 2025 Esperion Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.15812 EPS, expectations were $-0.09. Operator: Hello, ladies and ...

UBS executes its first tokenized fund transaction, LNRS opens APAC datacenter, MayStreet hits back in court, and more in this ...

Thank you, operator. Hello, and welcome, everyone. Today's earnings call will be led by Dr. Samantha Du, Zai Lab's Founder, CEO and Chairperson. She will be joined by Josh Smiley, President and Chief ...

Cidara Therapeutics' Q3 2025 call highlights accelerated Phase III CD388 progress, expanded patient reach, FDA breakthrough status, and $339M BARDA funding.

Recognized at #107 in inaugural ranking of 500 companiesBOCA RATON, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, ...

Caplyta’s most recent FDA approval is based on positive results from two Phase III clinical trials: Study 501 (NCT04985942) and Study 502 (NCT05061706). Both studies met their primary endpoint and key ...